IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.

INAB | NDAQ

Overview

Corporate Details

ISIN(s):: US45674E1091
LEI:
Country:: United States of America
Address:: EMPIRE STATE BUILDING, 10118 NEW YORK
Website:: https://www.in8bio.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform employs allogeneic, autologous, iPSC, and genetically modified approaches to develop novel cell therapies. A pioneer in the field, IN8BIO was the first company to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400 (Phase 2 for glioblastoma), INB-200 (Phase 1 for glioblastoma), and INB-100 (Phase 1 for leukemia), complemented by a portfolio of preclinical programs. The company's stated mission is to achieve "CANCER ZERO" by developing next-generation treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
BioAge Labs, Inc. Develops therapies for metabolic diseases like obesity by targeting the biology of human aging.	United States of America	BIOA
BioArctic Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.	Sweden	BIOA
BioAtla, Inc. Developing safer, conditionally active antibody therapies for solid tumor cancers.	United States of America	BCAB
BioCardia, Inc. Developing regenerative cell therapies for cardiovascular and pulmonary diseases.	United States of America	BCDA
Bioceltix S.A. Developing 'off-the-shelf' stem cell therapies for diseases in companion animals.	Poland	BCX
BIOCRYST PHARMACEUTICALS INC Develops oral small-molecule drugs for rare diseases like hereditary angioedema.	United States of America	BCRX
Biodexa Pharmaceuticals Plc Develops treatments for rare diseases, diabetes, and cancer using proprietary drug delivery tech.	United States of America	BDRX
Biofarm S.A. A top domestic manufacturer of pharmaceuticals, supplements, and soft gelatin capsules.	Romania	BIO
Biofrontera AG Biopharma firm specializing in photodynamic therapy for dermatological conditions like actinic keratosis.	Germany	B8F
Biofrontera Inc. Biopharma firm commercializing photodynamic therapy & antibiotics for skin conditions.	United States of America	BFRI